Clinical trials: Locally Advanced, Recurrent or Metastatic Malignancies
Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid System Neoplasm
Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer
This phase II/III trial studies how well physical activity with or without dexamethasone works in reducing cancer-related fatigue in patients with cancer that has spread to other places in the body or has come back.
- Conditions
- Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03583255
- Testing
- Dexamethasone, Exercise Intervention
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- M.D. Anderson Cancer Center
Sarcoma
Trastuzumab in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma
RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00104949
- Testing
- trastuzumab
- Volunteers
- 40 people
- Sponsor
- SWOG Cancer Research Network
NSCLC Stage IIIB, NSCLC Stage IIIC
Phase 2 Study of Dacomitinib in NSCLC
This is a multi-national, multi-centre, single-arm, open-label, Phase 2 clinical study of the efficacy and safety of first-line treatment with dacomitinib, with or without dose titration, in subjects with newly diagnosed stage…
- Conditions
- NSCLC Stage IIIB, NSCLC Stage IIIC, NSCLC Stage IV, Recurrent NSCLC
- Trial name
- NCT04027647
- Testing
- Dacomitinib
- Where
- 9 sites in Hong Kong, Malaysia and 3 more
- Volunteers
- 118 people
- Sponsor
- National Cancer Centre, Singapore
Locally Advanced, Recurrent or Metastatic Malignancies
SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors
This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Monotherapy and Combination Therapy in patients with advanced HER2-Expressing Solid Tumors.
- Trial name
- NCT07022002
- Testing
- SSGJ-705, PD-1/L1 inhibitor combined with chemotherapy, SSGJ-705 combined with chemotherapy
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Pancreatic Cancer
Gemcitabine With Antiangiogenic Peptide Vaccine Therapy in Patients With Pancreatic Cancer
The purpose of this study is to evaluate the safety, tolerability and immune response of different doses of VEGFR2-169 emulsified with Montanide ISA 51 in combination with gemcitabine and to determine the recommended phase II…
- Trial name
- NCT00622622
- Testing
- VEGFR2-169 and gemcitabine
- Where
- Japan
- Volunteers
- 21 people
- Sponsor
- Wakayama Medical University
Lung Cancer
Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal…
- Trial name
- NCT00547105
- Testing
- Erlotinib, SBRT
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Texas Southwestern Medical Center
Malignant Solid Neoplasms
Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment
The MOST Plus study is a two-period phase II clinical trial, conducted in patients with all types of progressive solid tumors after at least 1 prior systemic treatment regimen for advanced disease (in the absence of a validated…
- Trial name
- MOST plus (NCT02029001)
- Testing
- Nilotinib (400 mg BID), Everolimus (10 mg QD), Sorafenib (400 mg BID)
- Where
- 7 sites in France
- Volunteers
- 900 people
- Sponsor
- Centre Leon Berard
Squamous Cell Carcinoma of the Anal Canal
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy.
- Trial name
- NCT04472429
- Testing
- carboplatin, paclitaxel, retifanlimab
- Where
- 84 sites in United States, Australia and 11 more
- Volunteers
- 308 people
- Sponsor
- Incyte Corporation
Biliary Tract Cancer (BTC)
A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer
A Phase 2, multicenter, open-label, 2-stage study to assess the safety, tolerability, and efficacy of XERMELO in combination with first-line (1L) therapy (cisplatin [cis] plus gemcitabine [gem])
- Trial name
- TELE-ABC (NCT03790111)
- Testing
- telotristat ethyl
- Where
- 14 sites in United States
- Volunteers
- 53 people
- Sponsor
- TerSera Therapeutics LLC
Breast Cancer
Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer
This study is being done to find out how safe TAS-108 is and how well TAS-108 works on recurrent or recurrent inoperable breast cancer.
- Trial name
- NCT00166543
- Testing
- TAS-108
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- SRI International
Metastatic Breast Cancer
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of SKB264 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer.
- Trial name
- NCT06081959
- Testing
- SKB264, Eribulin, Capecitabine
- Where
- China
- Volunteers
- 376 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Colorectal Cancer
Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Cyclosporine may relieve the diarrhea caused by irinotecan.
- Trial name
- NCT00003950
- Testing
- cyclosporine, CPT-11
- Where
- 10 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of Chicago
Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma
Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma
This phase II trial studies how well temsirolimus and cixutumumab works in treating patients with locally advanced, metastatic, or recurrent soft tissue sarcoma or bone sarcoma.
- Conditions
- Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Osteosarcoma, Stage III Adult Soft Tissue Sarcoma
- Trial name
- NCT01016015
- Testing
- Cixutumumab, Laboratory Biomarker Analysis, Temsirolimus
- Where
- 24 sites in United States, Canada
- Volunteers
- 178 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Cancer
Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer
RATIONALE: Ridaforolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00770185
- Testing
- ridaforolimus, gene expression analysis, immunohistochemistry staining method
- Where
- 11 sites in Canada
- Volunteers
- 35 people
- Sponsor
- NCIC Clinical Trials Group
Estrogen Receptor Positive, Progesterone Receptor Positive
Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of alisertib when given together with fulvestrant in treating patients with hormone positive breast cancer that has spread to other parts of the body or has spread from…
- Conditions
- Estrogen Receptor Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer
- Trial name
- NCT02219789
- Testing
- Alisertib, Fulvestrant, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic
Esophageal Cancer, Gastric Cancer
Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.
- Trial name
- NCT00032123
- Testing
- erlotinib hydrochloride
- Where
- 107 sites in United States, Canada
- Sponsor
- SWOG Cancer Research Network
Urothelial Carcinoma, Urothelial Carcinoma Bladder
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
This study will compare the efficacy of 9MW2821+toripalimab versus 9MW2821 monotherapy in locally advanced or metastatic urothelial carcinoma patients who have not received any systemic treatment in the metastatic or advanced…
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urothelial Carcinoma of the Renal Pelvis and Ureter
- Trial name
- NCT06823427
- Testing
- 9MW2821, Toripalimab (JS001 )
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Pancreatic Ductal Adenocarcinoma, Pancreas Adenocarcinoma
Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)
A Phase II Open-Label Study of Enfortumab Vedotin in Patients with Previously Treated Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma (EPIC)
- Conditions
- Pancreatic Ductal Adenocarcinoma, Pancreas Adenocarcinoma, Pancreas Cancer
- Trial name
- NCT05915351
- Testing
- Enfortumab vedotin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Kansas Medical Center
Soft Tissue Sarcoma
A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue Sarcoma
The purpose of this study is to asess the safety and tolerability and efficacy of LVGN6051 combined with anlotinib in patient with soft tissue sarcoma.
- Trial name
- NCT05301764
- Testing
- LVGN6051 and Anlotinib
- Where
- 5 sites in China
- Volunteers
- 39 people
- Sponsor
- Lyvgen Biopharma Holdings Limited
Sarcoma
Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00033709
- Testing
- temozolomide, thalidomide
- Where
- United States
- Sponsor
- Herbert Irving Comprehensive Cancer Center